Abstract

http://ssrn.com/abstract=1632536
 
 

Footnotes (22)



 


 



Nanobiotechnology and the Food and Drug Administration


Jordan Paradise


Seton Hall University - School of Law

March 2010

Food and Drug Law Institute Update, pp. 23-35, March/April 2010

Abstract:     
Nanotechnology and nanobiotechnology have the potential toprovide tools for in vitro and in vivo diagnostics for much earlier detection of disease; facilitate targeted drug delivery and regenerative medical applications; supply anti-microbial coatings for implanted medical devices; and enable devices that seek, bind to, and destroy tumor cells. The Food and Drug Administration (FDA), as the gatekeeper to clearance and approval of medical and healthcare products in the United States, will be largely responsible for the oversight of the clinical research, approval and marketing of nanotechnology products for human use. At the present time, nanotechnology products are assessed on a case by case basis using existing regulations without specific categories, requirements or processes applicable to nanotechnology. FDA is reviewing and has approved human drug and medical devices that classify as "nanoproducts" using the established oversight paths for drugs and devices. This approach has provoked debate, with some arguing that nanotechnology warrants its own oversight provisions.

A July 2007 report of FDA's Nanotechnology Task Force flagged combination products utilizing nanotechnology as potentially problematic for the agency due to novel issues for regulation relating to scientific and technological features. While the creation of the OCP has resulted in a more collaborative approach to regulating emerging medical products crossing traditional boundaries among drugs, medical devices and biologics, the rapidly developing applications in nanomedicine that merge therapeutic drug delivery, imaging capabilities, and diagnostics may pose the next challenge. Unlike products at the macroscale, properties at the nanoscale and the distinction between chemical and mechanical action are not easily distinguishable or measurable. The challenge for FDA and other federal regulatory agencies grappling with the scope of nanotechnology will be determining whether nanotechnology products warrant additional regulations or whether current oversight can be adapted to the newly emerging capabilities and characteristics exhibited at the nanoscale.

Number of Pages in PDF File: 3

Accepted Paper Series


Download This Paper

Date posted: June 30, 2010  

Suggested Citation

Paradise, Jordan, Nanobiotechnology and the Food and Drug Administration (March 2010). Food and Drug Law Institute Update, pp. 23-35, March/April 2010. Available at SSRN: http://ssrn.com/abstract=1632536

Contact Information

Jordan K. Paradise (Contact Author)
Seton Hall University - School of Law ( email )
One Newark Center
Newark, NJ 07102-5210
United States
Feedback to SSRN


Paper statistics
Abstract Views: 331
Downloads: 48
Footnotes:  22
Paper comments
No comments have been made on this paper

© 2014 Social Science Electronic Publishing, Inc. All Rights Reserved.  FAQ   Terms of Use   Privacy Policy   Copyright   Contact Us
This page was processed by apollo7 in 0.641 seconds